Deprescribing Antipsychotics: a Multiple Case Study
NCT07343193 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2026-01-15
Summary
The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc.
The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments.
This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.
Conditions
- Psychotic Disorder
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-09
- Primary Completion
- 2026-09-30
- Completion
- 2026-09-09
Countries
- France
Study Locations
More Related Trials
-
Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
NCT01726335 ·Status: COMPLETED ·Phase: PHASE4
-
Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?
NCT03227562 ·Status: TERMINATED ·Phase: PHASE3
-
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159120 ·Status: COMPLETED ·Phase: PHASE4
-
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
NCT01207414 ·Status: COMPLETED ·Phase: PHASE4
-
Use of Antipsychotics in Palliative Care (NEUROPAL)
NCT03155685 ·Status: UNKNOWN
-
Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder
NCT00854919 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting
NCT01926912 ·Status: COMPLETED
-
Paliperidone Palmitate Flexible Dosing in Schizophrenia
NCT01281527 ·Status: COMPLETED ·Phase: PHASE3
-
Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia
NCT01724359 ·Status: COMPLETED ·Phase: PHASE4
-
Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain
NCT03130478 ·Status: COMPLETED
-
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
NCT00460512 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
NCT05633108 ·Status: COMPLETED
-
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
NCT00566631 ·Status: COMPLETED ·Phase: PHASE3
-
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
NCT00147394 ·Status: COMPLETED ·Phase: PHASE1
-
PREvent First Episode Relapse (PREFER)
NCT00220714 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study for Schizophrenia Relapse Prediction
NCT03629951 ·Status: COMPLETED
-
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
NCT05473741 ·Status: COMPLETED
-
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
NCT00215579 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
NCT01193153 ·Status: COMPLETED ·Phase: PHASE3
-
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
NCT00330863 ·Status: COMPLETED ·Phase: PHASE4
-
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
NCT01081769 ·Status: COMPLETED ·Phase: PHASE3
-
Switching Antipsychotics: Abrupt Discontinuation Versus Overlap
NCT02640300 ·Status: COMPLETED ·Phase: PHASE4
-
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
NCT01181960 ·Status: COMPLETED
-
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
NCT03130465 ·Status: UNKNOWN
-
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
NCT01855074 ·Status: COMPLETED ·Phase: PHASE4